Patents by Inventor Abhijit Suresh Bhat
Abhijit Suresh Bhat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11780935Abstract: The present invention relates to a polypeptide comprising 7 ?-strands A, B, C, D, E, F, and G sequentially connected together by connecting chains of amino acids, and a first ?-helix sequentially located on the EF chain between ?-strands E and F, wherein the ?-strands are arranged so as to form a first ?-sheet comprising ?-strands A, B, D, and E, and a second ?-sheet comprising ?-strands C, F and G, said first and second ?-sheets being covalently bonded together so as to form a first Ig domain; wherein the EF chain between ?-strands E and F comprises the sequence X1-X2-X3-X4-K5H6 (SEQ ID NO:98), and X1, X3 and X4 are each independently any amino acid residue, characterized in that X2 is selected from the group consisting of A, G, I, V, L, R, S, T, Q, P, N, M, H, W, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereof.Type: GrantFiled: June 9, 2020Date of Patent: October 10, 2023Assignee: Pfizer Healthcare IrelandInventors: Olivier Alexandre Laurent, Alice Lee, Richard Ryan Preston, David Tumelty, Wei Hong Yu, Abhijit Suresh Bhat, Anna Tempczyk-Russell
-
Publication number: 20220135638Abstract: The present disclosure provides GIP receptor agonist peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of diabetes, obesity, emesis, or a symptom or condition associated with diabetes, obesity, or emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are provided. Formula I: P1-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A341-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-P2 (SEQ ID NO: 4), or a salt thereof, wherein each symbol is as defined herein, with the proviso that the GIP receptor agonist peptide does not have an amino acid sequence as provided in SEQ ID NOs: 4-569 disclosed in PCT/JP2018/013540.Type: ApplicationFiled: September 24, 2019Publication date: May 5, 2022Inventors: Hiroshi IMOTO, Mari ADACHI, Yoko KANEMATSU, Taiji ASAMI, Ayumu NIIDA, Naoki NISHIZAWA, Derek Cecil COLE, Mack FLINSPACH, Nick SCORAH, Abhijit Suresh BHAT
-
Publication number: 20220016215Abstract: The present disclosure provides GIF receptor agonist peptide compounds having an activating action on GIF receptors and use of the GIF receptor agonist peptide as a medicament for the treatment and/or prevention of emesis. Specifically, a GIF receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are N provided. Formula (I) P1-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-A42-P2, wherein each symbol is as defined herein, with the proviso that the GIF receptor agonist peptide is not native human GIF having an amino acid sequence as set forth in SEQ ID NO: 1.Type: ApplicationFiled: September 24, 2019Publication date: January 20, 2022Inventors: Shiro TAKEKAWA, Tomoko MORIMOTO, Minoru MARUYAMA, Hiroaki NAGAI, Akira TANAKA, Hisanori MATSUI, Atsuko OBINATA, Derek Cecil COLE, Mack FLINSPACH, Nick SCORAH, Abhijit Suresh BHAT
-
Publication number: 20210147576Abstract: The present invention relates to a polypeptide comprising 7 ?-strands A, B, C, D, E, F, and G sequentially connected together by connecting chains of amino acids, and a first ?-helix sequentially located on the EF chain between ?-strands E and F, wherein the ?-strands are arranged so as to form a first ?-sheet comprising ?-strands A, B, D, and E, and a second ?-sheet comprising ?-strands C, F and G, said first and second ?-sheets being covalently bonded together so as to form a first Ig domain; wherein the EF chain between ?-strands E and F comprises the sequence X1-X2-X3-X4-K5H6 (SEQ ID NO:98), and X1, X3 and X4 are each independently any amino acid residue, characterized in that X2 is selected from the group consisting of A, G, I, V, L, R, S, T, Q, P, N, M, H, W, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereofType: ApplicationFiled: June 9, 2020Publication date: May 20, 2021Inventors: Olivier Alexandre Laurent, Alice Lee, Richard Ryan Preston, David Tumelty, Wei Hong Yu, Abhijit Suresh Bhat, Anna Tempczyk-Russell
-
Publication number: 20150057431Abstract: The present invention provides methods of treating (including preventing) a disease or condition associated with abnormal angiogenesis in a subject include administering a therapeutically effective amount of an AA targeting compound of the invention to the subject. The AA targeting compounds comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody.Type: ApplicationFiled: October 31, 2014Publication date: February 26, 2015Inventors: Curt William BRADSHAW, Abhijit Suresh BHAT, Jing-Yu LAI, Venkata R. DOPPALAPUDI, Dingguo LIU
-
Patent number: 8937048Abstract: The present invention provides various uses of VEGF binding peptides, including methods to treat disorders associated with abnormal angiogenesis. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules.Type: GrantFiled: August 27, 2012Date of Patent: January 20, 2015Assignee: Covx Technologies Ireland, LimitedInventors: Venkata Ramana Doppalapudi, Jing-Yu Lai, Bin Liu, Dingguo Liu, Joel Desharnais, Abhijit Suresh Bhat, Yanwen Fu, Bryan Douglas Oates, Gang Chen, Curt William Bradshaw
-
Patent number: 8741291Abstract: The present invention relates to Multifunctional Antibody Conjugates, comprising an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL?) comprising K188 according to Kabat numbering; a linker comprising the formula X-Y-Z, wherein Z is a group is covalently connected to the antibody through the side chain of K188, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety. The invention further provides specific MAC compounds and compositions of the invention.Type: GrantFiled: November 28, 2011Date of Patent: June 3, 2014Assignee: Covx Technologies Ireland, LimitedInventors: Abhijit Suresh Bhat, Curt William Bradshaw, Olivier Alexandre Laurent, Alice Lee, Richard Ryan Preston, David Tumelty, Lauren Diane Wood, Wei Hong Yu
-
Publication number: 20120321591Abstract: The present invention provides various uses of VEGF binding peptides, including methods to treat disorders associated with abnormal angiogenesis.Type: ApplicationFiled: August 27, 2012Publication date: December 20, 2012Inventors: Venkata Ramana Doppalapudi, Jing-Yu Lai, Bin Liu, Dingguo Liu, Joel Desharnais, Abhijit Suresh Bhat, Yanwen Fu, Bryan Douglas Oates, Gang Chen, Curt William Bradshaw
-
Patent number: 8293714Abstract: The present invention provides VEGF binding peptides. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules. Various uses of the peptides and compounds are provided, including methods to treat disorders associated with abnormal angiogenesis.Type: GrantFiled: April 29, 2009Date of Patent: October 23, 2012Assignee: Covx Technology Ireland, Ltd.Inventors: Venkata Ramana Doppalapudi, Jing-Yu Lai, Bin Liu, Dingguo Liu, Joel Desharnais, Abhijit Suresh Bhat, Yanwen Fu, Bryan Douglas Oates, Gang Chen, Curt William Bradshaw
-
Patent number: 8288349Abstract: The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.Type: GrantFiled: November 12, 2007Date of Patent: October 16, 2012Assignee: Covx Technology Ireland, Ltd.Inventors: Curt William Bradshaw, Abhijit Suresh Bhat, Jing-Yu Lai, Venkata R. Doppalapudi, Dingguo Liu
-
Publication number: 20120201809Abstract: The present invention relates to Multifunctional Antibody Conjugates, comprising an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL?) comprising K188 according to Kabat numbering; a linker comprising the formula X-Y-Z, wherein Z is a group is covalently connected to the antibody through the side chain of K188, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety. The invention further provides specific MAC compounds and compositions of the invention.Type: ApplicationFiled: November 28, 2011Publication date: August 9, 2012Applicant: COVX TECHNOLOGIES IRELAND, LIMITEDInventors: Abhijit Suresh Bhat, Curt William Bradshaw, Olivier Alexandre Laurent, Alice Lee, Richard Ryan Preston, David Tumelty, Lauren Diane Wood, Wei Hong Yu
-
Publication number: 20100003267Abstract: The present invention provides VEGF binding peptides. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules. Various uses of the peptides and compounds are provided, including methods to treat disorders associated with abnormal angiogenesis.Type: ApplicationFiled: April 29, 2009Publication date: January 7, 2010Inventors: Venkata Ramana Doppalapudi, Jing-Yu Lai, Bin Liu, Dingguo Liu, Joel Desharnais, Abhijit Suresh Bhat, Yanwen Fu, Bryan Douglas Oates, Gang Chen, Curt William Bradshaw